Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin

Biesma, Douwe H.

doi:10.1016/s0140-6736(94)91401-x

Cited by 63 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ANOVA analysis in the present study revealed significant increase in serum CA125 among patients with pelvic malignant tumor (p<0.001). This finding is similar to results of Asher V, et al, study in UK (2010) (88) , Kulkarni M, et al, study in USA (2013) (89) and Rani AK, et al, study in India (2012) (62) .CA125 is a high molecular weight glycoprotein and is the most useful tumor marker for epithelial ovarian carcinoma (90) .…”

Section: B Asupporting

confidence: 89%

“…Tumorrelated humoral factors with thrombopoietin-like activity (65,66) and overcompensated megakaryocytopoiesis due to tumorinduced disseminated intravascular coagulopathy (65)(66)(67) have been proposed in the etiology of reactive thrombocytosis in patients with malignant disease. Interleukin-6 (IL-6), granulocyte-macrophage colony stimulating factor (GmCSF), erythropoietin and tumor necrosis factor have been postulated to play a role in the development of thrombopoiesis and thrombocytosis (86)(87)(88)(89)(90)(91) . IL-6 is a potent stimulator of megakaryocytopoiesis and responsible for maturation of megakaryocytes (42,68) .…”

Section: B Amentioning

confidence: 99%

“…may also give rise to moderate elevation of serum CA125 (112) . The most common benign gynecological conditions associated with high serum CA125 are ovarian endometrioma and deeply infiltrating endometriosis (90) .…”

Section: B Amentioning

confidence: 99%

See 2 more Smart Citations

Clinical Significance of Thrombocytosis and CA125 as Predictor of Malignancy in Gynecological Pelvic Mass

Salamit¹

2018

Int.J.Curr.Res.Aca.Rev.

View full text Add to dashboard Cite

Article InfoWe attempted to determine the increasing of platelet counts (> 450.000 /microliter) and Cancer Antigen 125 (CA125) serum level (> 35 U/mL) as useful tools for predicting and confirming malignancy in gynaecological pelvic mass. A prospective unmatched hospital based case-control study carried out about One hundred & ten women were enrolled in our study, divided into two group 60 women were control group (free of gynaecological pelvic mass) which were considered as -eligible entrants‖ into the study. Other group include 50 women above 15 years old with gynaecological pelvic mass were all candidate for laparotomy and using different diagnostic methods like clinical examination, imaging techniques (U/S, CT scan and MRI) and laboratory test (platelet count, CA125 and Histopathology). The data of those were subjected to statistical analysis (sensitivity, specificity, accuracy, NPV and PPV) which calculated to considered if it is statistically significant or not. Serum CA125 and blood platelets count were tested for validity when used as a test to predict a diagnosis of malignancy in gynaecological pelvic mass differentiating it from benign gynaecological pelvic mass. Both tests showed a very high validity in diagnosis (ROC area >0.95), with serum CA125 showing a marginally higher validity (ROC area larger by 0.017 only). Both ROC areas were significantly higher than the 0.5 area associated with an equivocal test. Platelets counts had a perfect cut-off value of ≥385.000 All study subjects with a blood platelets count equal or greater than 385.000 were malignant, while everybody below this cut-off value was healthy. For serum CA125 testing negative at the highest sensitivity (100% sensitive) cut-off value of (≥27.1( would excluded a possible diagnosis of malignancy in favor of being healthy with 100% confidence. The optimum cut-off value is ≥41.7, which is also the 100% specific and thus 100% diagnostic cut-off value. Both blood platelet count (≥ 385 X 10 3 microlitter) & serum level of CA125 (≥ 41.7 U/mL) are useful predictor tools to confirm malignancy in gynecological pelvic mass.

show abstract

Section: B Asupporting

confidence: 89%

Section: B Amentioning

confidence: 99%

See 1 more Smart Citation

Clinical Significance of Thrombocytosis and CA125 as Predictor of Malignancy in Gynecological Pelvic Mass

Salamit¹

2018

Int.J.Curr.Res.Aca.Rev.

View full text Add to dashboard Cite

show abstract

“…Autologous donation has been demonstrated to be effective in reducing allogenic blood requirements. Allogeneic transfusion rates were reduced from 40%, 52% and 91% in the non-preoperative autologous donation group to 3%, 18% and 9% respectively in the preoperative autologous donor group in three cohort studies [22,23,24]. However pre-operative autologous donation is associated with a high rate of wasted blood units and is no longer deemed to be cost effective.…”

Section: Pre-operative Strategiesmentioning

confidence: 99%

Blood Conservation Strategies in Total Hip and Knee Arthroplasty

Liu¹,

Dan²,

Adivi³

2015

JISRF

View full text Add to dashboard Cite

Peri-operative blood management is one of a number of components important for successful patient care in total joint arthroplasty and surgeons should be proactive in its application. The aims of blood conservation are to reduce the risks of blood transfusion whilst at the same time maximizing haemaglobin in the post-operative period, thereby leading to a positive effect on early and long term outcomes and costs. An individualized strategy based on patient specific risk factors, anticipated blood loss and co-morbidities is useful in achieving this aim. Multiple blood conservation strategies are available in the pre-operative, intra-operative and post-operative periods and can be utilised either individually or in combination. Recent literature has highlighted the importance of identifying and correcting pre-operative anaemia, salvaging peri-operative red cells and the use of tranexamic acid in reducing blood loss. Given total hip and knee arthroplasty is an elective procedure, a zero allogenic blood transfusion rate should be the aim and an achievable goal.

show abstract

“…Allogeneic transfusion rates were reduced from 40%–52% to 3%–18% in the preoperative autologous donor group in two cohort studies2627). However preoperative autologous donation is associated with a high rate of wasted blood and is no longer deemed to be cost effective.…”

Section: Preoperative Strategiesmentioning

confidence: 99%

Blood Management Strategies in Total Knee Arthroplasty

Liu¹,

Dan

Martos³

et al. 2016

Knee Surg Relat Res

View full text Add to dashboard Cite

A perioperative blood management program is one of a number of important elements for successful patient care in total knee arthroplasty (TKA) and surgeons should be proactive in its application. The aims of blood conservation are to reduce the risk of blood transfusion whilst at the same time maximizing hemoglobin (Hb) in the postoperative period, leading to a positive effect on outcome and cost. An individualized strategy based on patient specific risk factors, anticipated blood loss and comorbidities are useful in achieving this aim. Multiple blood conservation strategies are available in the preoperative, intraoperative and postoperative periods and can be employed in various combinations. Recent literature has highlighted the importance of preoperative Hb optimization, minimizing blood loss and evidence-based transfusion guidelines. Given TKA is an elective procedure, a zero allogenic blood transfusion rate should be the aim and an achievable goal.

show abstract

Lower homologous blood requirement in autologous blood donors after treatment with recombinant human erythropoietin

Cited by 63 publications

References 22 publications

Clinical Significance of Thrombocytosis and CA125 as Predictor of Malignancy in Gynecological Pelvic Mass

Clinical Significance of Thrombocytosis and CA125 as Predictor of Malignancy in Gynecological Pelvic Mass

Blood Conservation Strategies in Total Hip and Knee Arthroplasty

Blood Management Strategies in Total Knee Arthroplasty

Contact Info

Product

Resources

About